

ANNOUNCING

# Canada's Premiere Virtual Cardiovascular Symposium

CardioMet'24 will be Canada's premiere, virtual cardiovascular symposium. Aimed at cardiovascular specialists, this multi-day virtual conference will highlight topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'24 will be unlike any other cardiovascular conference in Canada.

## 19th & 26th JANUARY 2024

12:00 – 6:00 pm EST

### Program Themes

#### 19th JANUARY 2024

- Imaging
- Structural Heart
- CAD/ACS

#### 26th JANUARY 2024

- Atrial Fibrillation
- Heart Failure
- Prevention

## Register Now!

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the McMaster University Continuing Professional Development Program. You may claim a maximum of 10 MOC Section 1 hours (credits are automatically calculated).

# CardioMet<sup>'24</sup>

Canada's Premiere Virtual Cardiovascular Symposium

### Opening Address



**Robert M. Califf**

MD  
Commissioner,  
Food and Drug Administration

### Keynote Speakers



**Ami Bhatt**

MD, FACC  
Chief Innovation Officer,  
American College of Cardiology



**Eugene Braunwald**

MD, MACC  
Harvard University

### Learning Objectives:

- ✓ Discuss the latest advances in cardiovascular risk factor management and prevention.
- ✓ Explain new developments in the management of heart failure and atrial fibrillation.
- ✓ Explore new imaging techniques employed in the management of structural heart disease.

### Registration

Visit: [www.ccrnmd.com](http://www.ccrnmd.com)

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com).



This program has received an educational grant from:

**Innovation Level – HLS Therapeutics**

**Impact Level – Amgen, Novartis**

**Benefactor Level – Anthos Therapeutics, AstraZeneca**

# AGENDA

Friday, January 19th, 2024



CardioMet<sup>24</sup>  
Canada's Premiere Virtual Cardiovascular Symposium



12:00 - 12:10 **Welcome and opening remarks**

**Milan Gupta**

## OPENING ADDRESS

12:10 - 12:30 **ROLE OF FDA IN COMBATting THE PUBLIC HEALTH THREAT OF CARDIOMETABOLIC DISEASE** **Robert M. Califf**

12:30 - 12:40 **DISCUSSION**

## KEYNOTE ADDRESS

12:40 - 1:00 **AI AND CARDIOLOGY: FRIEND OR FOE?** **Ami Bhatt**

1:00 - 1:10 **DISCUSSION**

## IMAGING Moderator: Jacob Udell

1:15 - 1:35 **ASSESSMENT OF CORONARY PLAQUE IN THE CATH LAB: BEYOND ANGIOGRAPHY** **Erick Schampaert**

1:35 - 1:55 **CARDIAC CT ANGIOGRAPHY: STRENGTHS AND LIMITATIONS** **Jonathan Leipsic**

1:55 - 2:15 **PRACTICAL APPLICATIONS OF CARDIAC MRI** **Kate Hanneman**

2:15 - 2:35 **DISCUSSION**

### Learning Objectives

- Describe the role of the FDA in helping to manage cardiometabolic disease
- Identify the current and future role of AI in cardiology
- Evaluate new and emerging strategies for coronary plaque assessment
- Describe the role and value of Cardiac CT angiography and cardiac MRI as a diagnostic tool

2:35 - 2:55 **REFRESHMENT BREAK**

## STRUCTURAL HEART Moderators: Margot Davis/Anique Ducharme

3:00 - 3:20 **CHALLENGES IN TAVR: BICUSPID VALVES AND ASYMPTOMATIC PATIENTS** **David Wood**

3:20 - 3:40 **MITRAL TEER: SELECTING THE RIGHT PATIENT** **Anique Ducharme**

3:40 - 4:00 **TRICUSPID REGURGITATION: INNOCENT BYSTANDER OR CULPRIT?** **Louis-Philippe David**

4:00 - 4:20 **DISCUSSION**

### Learning Objectives

- Explore the growing role of TAVR in bicuspid valves and asymptomatic patients
- Identify patients who can most benefit from Mitral TEER procedure
- Determine the association between tricuspid regurgitation and long-term outcomes

## CAD/ACS Moderators: Milan Gupta/Jacob Udell

4:25 - 4:45 **CULPRIT LESION OR COMPLETE REVASCUARIZATION FOR ACS?** **Shamir Mehta**

4:45 - 5:05 **DAPT FOLLOWING ACS: DOES ONE SIZE FIT ALL?** **Marc Bonaca**

5:05 - 5:25 **DOES PCI FOR STABLE CAD OFFER ANY BENEFITS?** **Rasha Al-Lamee**

5:25 - 5:45 **SHOULD COLCHICINE BECOME STANDARD THERAPY FOR CAD?** **Paul Ridker**

5:45 - 6:10 **DISCUSSION**

### Learning Objectives

- Distinguish the appropriate revascularization strategy for ACS patients
- Describe the evolving role of DAPT following ACS
- Review the clinical benefits of PCI in stable angina
- Identify the role of colchicine and vascular inflammation as a target of therapy

6:10 - 6:15 **MEETING CLOSE**

**Milan Gupta**

